1. A phase Ib/II translational study of sunitinib with neoadjuvant radiotherapy in soft-tissue sarcoma
- Author
-
Lewin, J, Khamly, KK, Young, RJ, Mitchell, C, Hicks, RJ, Toner, GC, Ngan, SYK, Chander, S, Powell, GJ, Herschtal, A, Te Marvelde, L, Desai, J, Choong, PFM, Stacker, SA, Achen, MG, Ferris, N, Fox, S, Slavin, J, Thomas, DM, Lewin, J, Khamly, KK, Young, RJ, Mitchell, C, Hicks, RJ, Toner, GC, Ngan, SYK, Chander, S, Powell, GJ, Herschtal, A, Te Marvelde, L, Desai, J, Choong, PFM, Stacker, SA, Achen, MG, Ferris, N, Fox, S, Slavin, J, and Thomas, DM
- Abstract
BACKGROUND: Preoperative radiotherapy (RT) is commonly used to treat localised soft-tissue sarcomas (STS). Hypoxia is an important determinant of radioresistance. Whether antiangiogenic therapy can 'normalise' tumour vasculature, thereby improving oxygenation, remains unknown. METHODS: Two cohorts were prospectively enrolled. Cohort A evaluated the implications of hypoxia in STS, using the hypoxic tracer (18)F-azomycin arabinoside (FAZA-PET). In cohort B, sunitinib was added to preoperative RT in a dose-finding phase 1b/2 design. RESULTS: In cohort A, 13 out of 23 tumours were hypoxic (FAZA-PET), correlating with metabolic activity (r(2)=0.85; P<0.001). Two-year progression-free (PFS) and overall (OS) survival were 61% (95% CI: 0.44-0.84) and 87% (95% CI: 0.74-1.00), respectively. Hypoxia was associated with radioresistance (P=0.012), higher local recurrence (Hazard ratio (HR): 10.2; P=0.02), PFS (HR: 8.4; P=0.02), and OS (HR: 41.4; P<0.04). In Cohort B, seven patients received sunitinib at dose level (DL): 0 (50 mg per day for 2 weeks before RT; 25 mg per day during RT) and two patients received DL: -1 (37.5 mg per day for entire period). Dose-limiting toxicities were observed in 4 out of 7 patients at DL 0 and 2 out of 2 patients at DL -1, resulting in premature study closure. Although there was no difference in PFS or OS, patients receiving sunitinib had higher local failure (HR: 8.1; P=0.004). CONCLUSION: In STS, hypoxia is associated with adverse outcomes. The combination of sunitinib with preoperative RT resulted in unacceptable toxicities, and higher local relapse rates.
- Published
- 2014